Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I dose-escalation and Phase II expansion study of FCN-011 in advanced solid tumors and NTRK fusion-positive advanced solid tumors
CTR20202377Phase 2Active
- Sponsor
- Fochon Biosciences
- Start
- Apr 2021
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of FCN-011 in Nonhematologic neoplasms, NTRK fusion-positive solid tumor, sponsored by Fochon Biosciences. Started Apr 2021; status: active.
02
Drugs
FCN-011
03
Conditions
Nonhematologic neoplasmsNTRK fusion-positive solid tumor
Beyond the preview
Go deeper on CTR20202377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202377.